Inovio Pharmaceuticals Inc INO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if INO is a good fit for your portfolio.
News
-
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine
-
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
-
Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting
-
INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024
-
INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
-
INOVIO Reports Inducement Grant Under Inducement Plan
-
INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split
-
INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader
Trading Information
- Previous Close Price
- $13.03
- Day Range
- $13.00–14.69
- 52-Week Range
- $3.89–14.69
- Bid/Ask
- $13.80 / $13.87
- Market Cap
- $324.38 Mil
- Volume/Avg
- 894,271 / 523,482
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 347.26
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 122
- Website
- https://www.inovio.com
Comparables
Valuation
Metric
|
INO
|
MRNA
|
002007
|
---|---|---|---|
Price/Earnings (Normalized) | — | 41.17 | 35.04 |
Price/Book Value | 2.53 | 3.05 | 3.31 |
Price/Sales | 347.26 | 6.25 | 7.49 |
Price/Cash Flow | — | — | 23.51 |
Price/Earnings
INO
MRNA
002007
Financial Strength
Metric
|
INO
|
MRNA
|
002007
|
---|---|---|---|
Quick Ratio | 3.47 | 3.21 | 2.69 |
Current Ratio | 3.60 | 3.42 | 3.88 |
Interest Coverage | −116.15 | −113.82 | 94.81 |
Quick Ratio
INO
MRNA
002007
Profitability
Metric
|
INO
|
MRNA
|
002007
|
---|---|---|---|
Return on Assets (Normalized) | −46.31% | −20.12% | 6.99% |
Return on Equity (Normalized) | −66.32% | −26.85% | 9.88% |
Return on Invested Capital (Normalized) | −59.56% | −26.68% | 7.71% |
Return on Assets
INO
MRNA
002007
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zcsjxbdh | Fbjl | $571.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Cqsmlzyfm | Cytftk | $107.8 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dcyctxr | Mdyncb | $106.1 Bil | |
MRNA
| Moderna Inc | Tcpqpwn | Pmkd | $42.3 Bil | |
ARGX
| argenx SE ADR | Nckbwxhz | Xqk | $23.7 Bil | |
BNTX
| BioNTech SE ADR | Bqrvmvgs | Fkmp | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qqkwcqrss | Wsvplcn | $19.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mzdvbqcq | Cxyldgn | $16.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mbcjltfzz | Zmxgy | $13.6 Bil | |
INCY
| Incyte Corp | Cckkgsfx | Skpkkw | $12.8 Bil |